Veterans Affairs committee  We don't. Clearly the ones we're aware of are the ones who come for help.

Veterans Affairs committee  Again, that's a difficult question, and it's outside my realm of expertise. What is clear, however, is that if we look specifically at post-traumatic stress disorder, we know that certain individuals are susceptible to this disorder and others are not. That susceptibility is ac

Veterans Affairs committee  Frankly, I believe that eventually it's going to be more than psychological testing. I think it's going to be biological testing. I think we're going to have biomarkers that could be genetic, epigenetic or hormonal markers. I believe that we need to develop true biological marker

Veterans Affairs committee  Very well.

Veterans Affairs committee  That's certainly a valid area for research. I do not think there is, or at least I'm not familiar with, any research on this transition period and the difficulties linked to this transition period. But I know for a fact that we've discussed with the assistant deputy minister of V

Veterans Affairs committee  Quite frankly, I could certainly get you some information on that. I can't really comment on it because it's always difficult to get information on those who don't come to us for treatment. What we do know, however, is that there are some areas, particularly the mental health a

Veterans Affairs committee  Thank you, Mr. Chair. I would first like to thank the Standing Committee on Veterans Affairs for this opportunity to discuss the issue of combat stress and its consequences on the mental health of veterans and their families. As in all matters of health, research is critical fo

Subcommittee on Neurological Disease committee  That's one of the huge issues. There are two problems. We didn't worry a lot about the variation in the anatomy of neck veins until this happened. That's one thing. And why didn't we worry? It was because there is a huge redundancy in the number of veins and capacity for draina

Subcommittee on Neurological Disease committee  It's certainly going to benefit patients. The work is going to go faster as they benefit from one another's experience. I would say that it's a microcosm of what's going on more and more in science. There is always a mix of collaboration and competition, but there is more collabo

Subcommittee on Neurological Disease committee  Thank you very much.

Subcommittee on Neurological Disease committee  Thank you, Madam Chair.

Subcommittee on Neurological Disease committee  There are several elements to your questions. I'll try to go through them rapidly. First, I want to tell you how important it is that MPs care and how important is your statement about the need for evidence-based practice.

Subcommittee on Neurological Disease committee  It's the basis of our medical practice in this country, and at times it's tough to follow. You feel for those patients who have very few options right now. Quite frankly, the last thing I want to do is blame the patients, because I understand that. We have a role to explain to th

Subcommittee on Neurological Disease committee  You may well be right, but I can tell you that it's not acceptable; we will not condone it, and we'll try to, as I said, by working with the professional associations and colleges, impress upon these groups the importance that patients are seen and are treated. The only thing I c

Subcommittee on Neurological Disease committee  Actually, there are several.... An article came out yesterday about another breakthrough study by a British group using stem cells to regenerate myelin on the demyelinated fascicles. There are several drugs in the pipeline. One was recently accepted by Health Canada. We learned a